LUCIUS 卢修斯 阿培利司 Alpelisib乳腺癌

阿培利司

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Alpelisib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

乳腺癌

Each tablet contains Alpeltstb ............ 150 mg
Indication:
LuciAlpe is a kinase inhibitor indicated in

LUCIUS

combination with Fulvestrant for
of postmenopausal women, and men, witl

PHARMACEUTICALS

hormone receptor (HR)-positive, human
epldermal growth tactor receptor 2(HER2)
negative, PIK3CA-mutated, advanced or
metastatic breast cancer as detected by an

LuciAlpe®

FDA-approved test following proeression on or
after an endocrine-based regimen.
Dosage and Use
es of LuciAlpe is 300 mg
once daily slaken oralle.

Alpelisib film coated tablets

FDA批准

Patients should take their dose of LuciAlpe at
approximately the same time each day.
Swallow LuciAlpe tablets whole itablets
should not be chewed, crushed or split prior 1

150mg

swallowing
Storage: in a dry place and store at 20°C to 25°C
Warning:
Keep medicine out of the reach of Children. Do
nol administered LuciAlpe in Pregnancy and
PLFISE GOPDACKACEINSER
Preonaney snd
Manufactured and Marketed by

UCIUS

权威认证

gviage. Xaythany distriet
chuane Capital, Laos
Warning : To be sold by retail on prescription
Aeeered physiciaos onlv, and as drrested
the prysician

28 film-coated tablets

口碑质量

适应症:
用于经基于内分泌的治疗方案治疗后疾病进展的携带PIK3CA突
变的激素受体阳性、人表皮生长因子受体-2阴性(HR+/HER2-)的

晚期或转移性乳腺癌患者。
推荐剂量:
1 、 推 荐 剂 量 :300mg( 两 片 150mg 药 片 ), 每 天 一 次 , 与 食 物 一 起 口 服
2、整片吞服,不能咀嚼、碎裂、破碎药片。
3、对于不良反应,请考虑剂量中断,剂量减少或停药